Compare Amylx Pharmaceuticals Inc (AMLX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Snap On Incorporated trades at $408.11 (market cap $21.30B). The key difference: Snap On Incorporated is far larger — about 8.1× Amylx Pharmaceuticals Inc's market cap, and Snap On Incorporated pays a 2.37% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SNA | |
|---|---|---|
Market Cap | $2.64B | $21.30B |
Sector | Health | Technology |
52-Week High | $24.19 | $419.31 |
52-Week Low | $7.82 | $321.38 |
Enterprise Value | $2.39B | $20.93B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Snap-on Incorporated (SNA) trades at $407.78, down 0.81% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.6% net income margin and 17.58% ROE, though valuation metrics appear elevated at P/E 21.01 and P/S 4.12. Recent Q2 2026 earnings beat expectations with $4.96 EPS, while the $100 million Diesel Laptops acquisition expands diagnostic capabilities.
SNA offers growth potential through strategic acquisitions and operational efficiency, with analyst consensus target of $455.33 suggesting 11.7% upside. Key risks include integration challenges from recent acquisitions and premium valuation pressure. The bullish technical setup combined with strong profitability supports a positive medium-term outlook despite near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
